Monocyte Chemoattractant Protein-1 in Patients with Peripheral Arterial Disease

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2004 Jun 19

PMID 15203564

Citations 6

Authors

Jana Petrkova

Jaroslava Szotkowska

Zuzana Hermanova

Jan Lukl

Martin Petrek

Affiliations

Soon will be listed here.

Abstract

Background: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD.

Methods: Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation (p < 0.05).

Results: MCP-1 (pg/ml) was increased in patients compared with in controls (mean+/-standard error of the mean: PAD group, 748+/-60; control group, 459+/-27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein.

Conclusion: Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.

Citing Articles

Prediction of Peripheral Artery Disease Prognosis Using Clinical and Inflammatory Biomarker Data.

Li B, Shaikh F, Zamzam A, Raphael R, Syed M, Younes H J Inflamm Res. 2024; 17:4865-4879.

PMID: 39070129 PMC: 11278072. DOI: 10.2147/JIR.S471150.

Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease.

Kavurma M, Bursill C, Stanley C, Passam F, Cartland S, Patel S Front Cardiovasc Med. 2022; 9:1054576.

PMID: 36465438 PMC: 9709122. DOI: 10.3389/fcvm.2022.1054576.

Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Iftimie S, Garcia-Heredia A, Pujol I, Ballester F, Fort-Gallifa I, Simo J Eur J Clin Microbiol Infect Dis. 2016; 35(9):1417-24.

PMID: 27334497 DOI: 10.1007/s10096-016-2679-8.

Immunohistochemical analysis of paraoxonases and chemokines in arteries of patients with peripheral artery disease.

Hernandez-Aguilera A, Sepulveda J, Rodriguez-Gallego E, Guirro M, Garcia-Heredia A, Cabre N Int J Mol Sci. 2015; 16(5):11323-38.

PMID: 25993297 PMC: 4463702. DOI: 10.3390/ijms160511323.

Elevated monocytes in patients with critical limb ischemia diminish after bypass surgery.

Magri D, Vasilas P, Muto A, Fitzgerald T, Fancher T, Feinstein A J Surg Res. 2009; 167(1):140-50.

PMID: 19854451 PMC: 2895962. DOI: 10.1016/j.jss.2009.06.014.

References

Gerard C, Rollins B . Chemokines and disease. Nat Immunol. 2001; 2(2):108-15. DOI: 10.1038/84209. View

Mackay C . Chemokines: immunology's high impact factors. Nat Immunol. 2001; 2(2):95-101. DOI: 10.1038/84298. View

Dwivedi A, Anggard E, Carrier M . Oxidized LDL-mediated monocyte adhesion to endothelial cells does not involve NFkappaB. Biochem Biophys Res Commun. 2001; 284(1):239-44. DOI: 10.1006/bbrc.2001.4955. View

Aukrust P, Damas J, Gullestad L, Froland S . Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets. Clin Exp Immunol. 2001; 124(3):343-5. PMC: 1906089. DOI: 10.1046/j.1365-2249.2001.01527.x. View

Fuse K, Kodama M, Hanawa H, Okura Y, Ito M, Shiono T . Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Exp Immunol. 2001; 124(3):346-52. PMC: 1906075. DOI: 10.1046/j.1365-2249.2001.01510.x. View

Ouriel K . Peripheral arterial disease. Lancet. 2001; 358(9289):1257-64. DOI: 10.1016/S0140-6736(01)06351-6. View

Matsui K, Ikeda U, Murakami Y, Yoshioka T, Shimada K . Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J. 2003; 145(2):330-3. DOI: 10.1067/mhj.2003.145. View

Brevetti G, Piscione F, Silvestro A, Galasso G, Di Donato A, Oliva G . Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003; 89(6):1058-63. View

McDermott M, Green D, Greenland P, Liu K, Criqui M, Chan C . Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003; 92(2):194-9. DOI: 10.1016/s0002-9149(03)00537-x. View

10.

Barretto S, Ballman K, Rooke T, Kullo I . Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location. Vasc Med. 2003; 8(2):95-100. DOI: 10.1191/1358863x03vm475oa. View

11.

Valente A, Rozek M, Sprague E, Schwartz C . Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation. 1992; 86(6 Suppl):III20-5. View

12.

Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, SHIOI T . Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 1997; 29(1):419-23. DOI: 10.1006/jmcc.1996.0285. View

13.

Meijer W, Hoes A, Rutgers D, Bots M, Hofman A, Grobbee D . Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998; 18(2):185-92. DOI: 10.1161/01.atv.18.2.185. View

14.

Aukrust P, Ueland T, Muller F, Andreassen A, Nordoy I, Aas H . Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998; 97(12):1136-43. DOI: 10.1161/01.cir.97.12.1136. View

15.

Gullestad L, Simonsen S, Ueland T, Holm T, Aass H, Andreassen A . Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol. 1999; 84(9):999-1003. DOI: 10.1016/s0002-9149(99)00487-7. View

16.

Ramirez-Tortosa M, Urbano G, Lopez-Jurado M, Nestares T, Gomez M, Gonzalez J . Lifestyle changes in free-living patients with peripheral vascular disease (Fontaine stage II) related to plasma and LDL lipid composition: a 15 month follow-up study. Clin Nutr. 1999; 18(5):281-9. DOI: 10.1016/s0261-5614(98)80025-3. View

17.

Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R . IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract. 2000; 48(2):127-38. DOI: 10.1016/s0168-8227(99)00147-3. View

18.

Damas J, Eiken H, Oie E, Bjerkeli V, Yndestad A, Ueland T . Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res. 2000; 47(4):778-87. DOI: 10.1016/s0008-6363(00)00142-5. View

19.

Call D, Nemzek J, Ebong S, Bolgos G, Newcomb D, Remick D . Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol. 2001; 158(2):715-21. PMC: 1850325. DOI: 10.1016/S0002-9440(10)64014-X. View

20.

Jilma-Stohlawetz P, Homoncik M, Drucker C, Marsik C, Rot A, Mayr W . Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion. 2001; 41(3):378-81. DOI: 10.1046/j.1537-2995.2001.41030378.x. View